GSK plc announced on May 18, 2026, that Japan's Ministry of Health has expanded the approval of their RSV vaccine, Arexvy, to include adults aged 18-49 at increased risk for severe RSV outcomes. This is the first RSV vaccine approved for this age group in Japan, recognizing the health risks for those with chronic conditions.